REFRACTORY CHILDHOOD OSTEOSARCOMA
Clinical trials for REFRACTORY CHILDHOOD OSTEOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHILDHOOD OSTEOSARCOMA trials appear
Sign up with your email to follow new studies for REFRACTORY CHILDHOOD OSTEOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with resistant cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had spread, returned, or stopped responding to treatment. The drug targets tumors with specific changes in FGFR genes. The main goal was to see if the drug could shrink or stop t…
Matched conditions: REFRACTORY CHILDHOOD OSTEOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Engineered immune cells take on tough childhood cancers in new trial
Disease control TerminatedThis early-stage trial tests a personalized cell therapy called GD2CART for children and young adults with osteosarcoma or neuroblastoma that has returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack ca…
Matched conditions: REFRACTORY CHILDHOOD OSTEOSARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:31 UTC